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Abstract 
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Background: Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) share clinical, 
pathological, immunohistochemical and molecular features, though PDS is associated with a more aggressive 
behavior.  
Methods: We revised 71 tumors fulfilling criteria for AFX and PDS to further stratify their biological potential.  
Results: Lesions predominate on the scalp of elderly men, were frequently ulcerated, one case presented 
necrosis, one vascular, and another perineural invasion. Fifty-one tumors were limited to reticular dermis 
(71.8%), 20 invaded subcutaneous tissue, focally in 13 cases (18.3%), and   diffusely in seven (9.9%). A 
significant more frequent subcutaneous invasion was observed in tumors showing predominantly spindle 
compared to pleomorphic/mixed cell morphology (p= 0.02). At a follow-up of 17-125 months, 4 cases 
recurred locally, 4, 6, 10 and 13 months after surgery; no metastases were observed. Three tumors were 
composed of spindle cells, and one of clear cells. Three cases had margins focally involved, the fourth case 
had clear margins. 
Conclusion: Depth of invasion and state of margins are criteria predicting prognosis in AFX/PDS; in addition, 
spindle cell morphology seems to be related to a more infiltrative pattern of growth and consequently 
aggressiveness. Grouping these tumors on a morphologic base could contribute to clarify their different 
biological behavior. 
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Introduction 
   Atypical fibroxanthoma (AFX) is a tumor described by Helwig in 19631 of still debated origin, arising on sun-
exposed skin of elderly patients, with very low propensity of recurrence and almost no metastatic potential2,3. 
Pleomorphic dermal sarcoma (PDS) is a tumor with overlapping clinical, pathological and 
immunophenotypical features, but with referred higher recurrence rate and metastatic potential4,5. Recent 
studies found similar genetic alterations in the two neoplasms6-8. Both AFX and PDS are diagnoses of 
exclusion, to be made after careful immunohistochemical study, in order to not miss other neoplasms such 
as squamous cell carcinoma, melanoma, leiomyosarcoma or angiosarcoma9. 
   Apart from few histologic criteria4, it is still unclear what really differentiates these two entities. Cases of 
metastatic AFX have been reported10-13, while, on the other hand, PDS indicates a category of tumors arising 
in the same clinical setting of AFX but showing more propensity to recur or metastasize5. The literature is 
somewhat confusing, partly because of different diagnostic criteria used by the authors12-14, partly for 
incomplete immunohistochemical characterization of tumors, especially in older research10. In the present 
study, we revised clinical and pathological features, immunohistochemical profiles, and follow-up of a series 
of cutaneous lesions fulfilling histologic criteria of AFX and PDS. Subsequently, we focused on the histological 
characters related to subcutaneous invasion, in the attempt to further stratify the risk of recurrence in these 
cutaneous neoplasms. 
 
Materials and methods 
   All skin biopsies consecutively diagnosed as AFX or sarcoma NOS, in the period 2009-2019, were retrieved 
from our archives. Criteria of inclusion in the study were complete clinical data, representative tumoral tissue, 
and immunohistochemical characterization of lesions; cutaneous involvement by sarcoma of deep soft tissue, 
as well as cutaneous metastases from distant sarcomas were excluded. After revision of all clinical data and 
slides, a total of 71 cases resulted eligible for the study. Clinical parameters were represented by patients’ 
gender and age, anatomic site of lesions, type of surgery, and development of recurrence/metastasis.  
   Hematoxylin-eosin slides were reviewed, and the following features were registered: maximum diameter of 
tumor; type of cellular components, e.g. pleomorphic, epithelioid,  spindle, other rare types; presence of 
ulceration, necrosis, vascular invasion, perineural invasion; infiltration beyond reticular dermis into 
subcutaneous tissue, subdivided in focal, when tumor focally exceeded reticular dermis, and diffuse 
infiltration, when tumor deeply infiltrated subcutis; state of margins. Immunohistochemical stains performed 
were recorded for each case, as well as the presence of any adjacent tumors.  
   Statistical analysis was performed by using a chi-squared test; a p value <0.05 was considered statistically 
significant. 
 
Results 
   Clinical data of 71 cases included in the study are shown in table 1. Patients were predominantly male, and 
most cases developed in the seventh and eight decades.  Anatomic site was the scalp in more than half of the 
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cases. All patients, but one lost at follow-up, underwent surgical excision d’emblée or incisional biopsy 
followed by surgical excision. Follow-up ranged between 17 and 125 months; 4 cases recurred locally, 4, 6, 10 
and 13 months after surgery; after re-excision no further recurrence or metastases were observed. 
   Histological revision of slides demonstrated that diameter of lesions ranged between 0.3 and 12.8 cm 
(mean: 1.7 cm). The prevalent cell type was pleomorphic/ mixed epithelioid and spindle (37 cases) (fig. 1A), 
followed by predominantly spindle cell (28 cases), whereas very few cases featured epithelioid (2), clear (2), 
or keloidal aspect (2). Ulceration was present in 46 cases (64.7%). Vascular invasion was observed in one case 
(fig. 1B); necrosis was registered in another and perineural invasion in a further case. Tumors limited to 
reticular dermis amounted to 51 (71.8%) (fig. 1C), whereas invasion of subcutaneous tissue was observed in 
20 cases, particularly 13 cases (18.3%) showed focal infiltration of adipose tissue (fig. 1D), whereas in 7 cases 
(9.9%) subcutaneous tissue resulted diffusely infiltrated (fig. 1E,F), with one case involving also the cranial 
theca. Of 37 pleomorphic/mixed cell tumors, subcutaneous tissue was infiltrated focally in 4 cases and 
diffusely in one case; of 28 spindle cell tumors, 8 cases infiltrated focally and 5 cases diffusely the subcutis; 
one case of clear cell type showed focal and one case of epithelioid type showed diffuse infiltration of adipose 
tissue. Dimension and ulceration did not correlate with amount of tumoral invasion, whereas we found a 
significant more frequent subcutaneous invasion, by considering together focal and diffuse pattern, in cases 
showing predominantly spindle compared to pleomorphic/mixed cell morphology (p= 0.02). After surgery, 
margins were focally involved in 7 cases. Immunohistochemical profile of tumors are shown in table 2; 
expression did not differ among cases with different cellular type or level of infiltration. Associated cutaneous 
lesions were represented mainly by actinic keratosis (26 cases), followed by squamous cell carcinoma (4) and 
basal cell carcinoma (1) and were found in 31 cases, with no difference related to invasiveness or cellular type 
of tumors. 
   Recurrence was observed in 4 out of 71 cases (5.6%). Specifically, none of the 51 cases limited to dermis 
recurred, including the case featuring perineural infiltration; recurrence occurred in one out of 13 cases 
showing focal infiltration of subcutis (7.7%), and in 3 of 7 cases showing diffuse infiltration (42.8%). The case 
showing vascular invasion, focally infiltrating adipose tissue, and the case with necrosis, also deeply 
infiltrating subcutis, did not recur. Statistical analysis was not performed given the low number of events. 
Patients with recurrent tumors were 3 males and one female. Dimensions of recurrent tumors ranged 
between 0.6 and 4.0 cm in diameter; two cases were localized on the scalp, one on the forehead and another 
on the cheek. Three tumors were composed of spindle cells, and one of clear cells. Three cases had focally 
involved margins, whereas margins were clear in the fourth case.  
 
Discussion 
   AFX and PDS are diagnoses of exclusion and differentiation from other primary cutaneous tumors arising 
on sun-exposed skin, such as squamous cell carcinoma, particularly the spindle cell subtype, melanoma, leio-
myosarcoma and angiosarcoma, deserves exhaustive immunohistochemistry. AFX and PDS represent a spec-
trum of tumors with similar histopathological, immunophenotypical, and molecular features9,15. Ulceration is 
frequently observed in both entities and does not affect tumor behavior. Our study aimed to analyze all con-
secutive tumors fulfilling criteria for either AFX or PDS, diagnosed during an eleven-years long period of time 
in our institution, therefore it was performed on routine cases, avoiding the bias of collection series or referral 
cases.  
   Analogously to previous studies, in our experience these tumors typically present as dermal based, often 
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ulcerated neoplasms arisen on chronically sun exposed skin, especially the scalp, of elderly people. Roughly 
18% of our cases infiltrated focally and 10% diffusely the subcutaneous tissue. They demonstrated no meta-
static evolution and a very low propensity to recur (5.6%) as a whole. In agreement with the current literature, 
recurrence occurred in those cases infiltrating the subcutis, particularly in deeply infiltrating tumors, and 
mostly in those with margin involvement. We did not register cases with distant metastasis, to lymph nodes 
or lung, as reported in few series of AFX or PDS4,5,12,15, although our percentage of recurrence approximates 
that of other studies5,15.  Interestingly, we found that spindle cell morphology was significantly more fre-
quently associated to subcutaneous invasion, hence to recurrence, in fact three out of 4 recurrent tumors in 
our study were composed by spindle cells. In their paper, Wang et al. reported 11 cases of “metastatic atypical 
fibroxanthoma”, of which at least seven infiltrating subcutis; eight cases showed spindle cell morphology, 
whereas the others were partly made up of spindle cells12. Two more cases of AFX with cutaneous or satellite 
metastasis have been reported11,13; both tumors were mainly composed of spindle cells, and at least focally 
infiltrated adipose tissue. These observations suggest that spindle cell morphology could be related to a more 
infiltrative pattern of growth and consequently aggressive behavior. This aspect has never been fully ad-
dressed in the literature. In a study of 32 PDS, Miller et al describe cases with recurrences and/or metastasis, 
but no correlation is made with main cellular type4. In a retrospective review of the literature, all reported 
cases of AFX with recurrences and metastases were reconsidered, focusing on their treatment and manage-
ment, but the main cellular composition of tumors is not specified16. Another study investigated a series of 
undifferentiated pleomorphic sarcomas (UPS) subdivided histologically in two main groups, anaplastic/pleo-
morphic vs spindle/epithelioid, failing to find different behavior among the two groups17; nevertheless, the 
study included tumors not only from the head and neck, but also from the trunk and extremities, therefore 
it is not properly comparable to our study.  
   Molecular studies have failed to demonstrate alterations substantially discriminating AFX from PDS, to 
date6-8, inducing some authors to consider AFX as the “not infiltrating precursor of PDS”8. From the immuno-
histochemical point of view, we did not find a different profile among tumors with different cellular types. 
Toll and coworkers evaluated the immunohistochemical expression of EMT (epithelial to mesenchymal tran-
sition) markers in a series of AFX and PDS, concluding that EMT does not play a role in the development of 
these tumors18. On the contrary, a more recent study found that EMT is upregulated in AFX. Since EMT is 
associated with progression and metastasis, the authors suggest that this could explain the recurrences or, 
more rarely, metastases observed in AFX and PDS19. Unfortunately, this study investigated a low number of 
cases, without indication of their follow-up. EMT has been found, also, to play a role in the sarcomatous 
differentiation of dermatofibrosarcoma protuberans20, known to confer a high risk of evolution21. The hypoth-
esis that EMT is upregulated particularly in tumors of the AFX/PDS group featuring spindle cell/sarcomatoid 
morphology, could be matter of further investigations.  
   In conclusion, in our experience, by strictly applying clinical, pathological and immunohistochemical criteria, 
few cases of AFX/PDS should be expected to recur and exceptionally to metastasize. Deepness of infiltration 
and type of excision proved to be robust prognostic criteria. On the other hand, our results suggest that 
studying these tumors grouped on a morphologic base, particularly focusing on the predominant spindle cell 
vs pleomorphic/mixed cell pattern, could contribute to clarifying their different biological behavior, and 
possibly to go beyond the definitions AFX and PDS.   
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Table 1: Clinical data of 71 cases studied 
 
Age Gender Anatomical site Recurrence 
<60: 1 M: 56 Scalp: 42 4 (3M/1F) 
60-69: 10 F: 15 Ear: 11   
70-79:24  Cheek: 3  
80-89: 31 M/F = 3.8:1 Nose: 4 Follow-up 
≥90: 5  Forehead: 5 17-125 months 
  Face N.O.S.: 6  
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Table 2: Immunohistochemical profile of cases studied 
 
Antibody clone N# positive/total 
Cytokeratin MNF-116    (DAKO) 0/71 
S-100 protein 4C4.9         (Ventana) 0/71 
CD10 SP67          (Ventana) 45/45 
Smooth-muscle actin 1A4            (Ventana) 21/32 
CD68 PG-M1      (Ventana) 20/24 
p63 4A4           (Ventana) 1 (focal)/41 
p40 BC28         (Ventana) 0/10 
Desmin DER11       (Ventana) 0/39 
EMA E29            (Ventana) 0/7 
CK5/6 D5/16B4  (Ventana) 0/2 
CD34 QBend10  (Ventana) 0/25 
CD31 JC70          (Ventana) 0/13 
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Legend to figure 
Fig. 1 Tumor with mixed cell morphology (A, 200x, H&E); vascular invasion (arrow); the tumor, also, focally 
infiltrated adipose tissue and did not recur (B, H&E, 100x); tumor limited to the dermis (C, 100x, H&E);  tumor 
with predominantly spindle cell morphology, focally infiltrating adipose tissue (D, 40x, H&E); tumor with 
spindle cell morphology, diffusely infiltrating subcutis (E, 40x; H&E).; the same tumor, negative for CD34 
immunostaining, recurred after 10 months (F, 100x, H&E). 
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